The expression of hTR and hTERT in human breast cancer: correlation with clinico-pathological parameters
Saied Hosseini-Asl1, Morteza Atri2, Mohammad H Modarressi1, Mohamed Salhab3, Kefah Mokbel3 and Parvin Mehdipour*1

Address: 1Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, IR, Iran, 2Cancer Institute, Tehran University of Medical Sciences/Day General Hospital, Tehran, IR, Iran and 3St George’s Hospital, London, SW17 0QT, UK

Email: Saied Hosseini-Asl - saied.hosseiniasl@gmail.com; Morteza Atri - b_atri@yahoo.com; Mohammad H Modarressi - modaresi@sina.tums.ac.ir; Mohamed Salhab - msalhab1@excite.com; Kefah Mokbel - kefahmokbel@hotmail.com; Parvin Mehdipour* - mehdipor@sina.tums.ac.ir

* Corresponding author

Abstract
Background: Telomerase is a ribonucleoprotein enzyme that synthesises telomeres after cell division and maintains chromosomal stability leading to cellular immortalization. Telomerase has been associated with negative prognostic indicators in some studies. The present study aims to detect any association between telomerase sub-units: hTERT and hTR and the prognostic indicators including tumour’s size and grade, nodal status and patient’s age.

Methods: Tumour samples from 46 patients with primary invasive breast cancer and 3 patients with benign tumours were collected. RT-PCR analysis was used for the detection of hTR, hTERT, and PGM1 (as a housekeeping) genes expression.

Results: The expression of hTR and hTERT was found in 31(67.4%) and 38 (82.6%) samples respectively. We observed a significant association between hTR gene expression and younger age at diagnosis (p = 0.019) when comparing patients ≤ 40 years with those who are older than 40 years. None of the benign tumours expressed hTR gene. However, the expression of hTERT gene was revealed in 2 samples.

No significant association between hTR and hTERT expression and tumour’s grade, stage and nodal status was seen.

Conclusion: The expression of hTR and hTERT seems to be independent of tumour’s stage. hTR expression probably plays a greater role in mammary tumourogenesis in younger women (≤ 40 years) and this may have therapeutic implications in the context of hTR targeting strategies.

Background
Telomerase is an RNA dependant DNA polymerase, the function of which is to synthesise the repetitive nucleotide sequence (TTAGGG in humans) forming the telomeres at the end of chromosomes [1]. These telomeres form caps on the chromosomes that prevent fusion of chromosomal ends during cell division. The DNA polymerase is unable to fully replicate the ends of linear DNA and genetic material is lost and this can result in chromosomal instability and cellular senescence. Without telomerase activity, each
round of nuclear division results in shortening of telomeres and reaching a critical length seems to trigger off cellular apoptosis. Therefore, telomerase activity seems to stabilize telomeres and to be responsible for compensating about 65 bp in eukaryotic chromosomal ends, thus, leading to cellular immortality [1-8] and, may therefore, be a critical step in carcinogenesis [9,11].

Telomerase is active in 70–90% of malignant tissues and many immortal cell lines, but most somatic cells have no detectable telomerase activity [5,10,11].

Human telomerase consists of an RNA subunit; human telomerase RNA (hTR) [12], a protein component (human telomerase associated protein 1 (hTEP1) [13] and the catalytic subunit hTERT (human telomerase reverse transcriptase) [14-16]. Of these subunits telomerase activity requires the presence of hTR, which is the RNA template for the telomeric repeat, and hTERT, which is the reverse transcriptase. Furthermore, it is reported that the induction of hEST2 mRNA expression is required for the telomerase activation that occurs during cellular immortalization and tumor progression. [17]. Several studies have shown that disrupting the function of telomerase RNA leads to progressive shortening of telomeres, suggesting that this component plays an essential role in telomerase function [18].

The genes coding for the RNA subunits of telomerase have been cloned from a wide variety of species [12,19] and have been shown to be essential for telomerase function in vivo [18,20-23]. In humans, genes coding for hTERT and hTR have been cloned and mapped to chromosomes 5p15.33 and 3q26.3 respectively [4,24].

Expression of hTERT was found to be at high levels in malignant tumors and cancer cell lines but not in normal tissues or telomerase-negative cell lines, and a strong correlation was found between hTERT expression and telomerase activity in breast cancer [25].

We previously reported that telomerase reactivation was significantly associated with advanced breast cancer stage, histopathological grade [26] and nodal metastasis with no significant association between telomerase activity and menopausal status, or tumor size [27]. Furthermore, we reported no significant association between tumour hTERT expression and patient’s age, tumour size, grade, nodal metastasis, estrogen receptor (ER) positivity and lymphovascular (LVI) [28,29].

The aim of this study was to examine the expression of telomerase subunits hTERT and hTR and correlate them with different clinical and pathological parameters including tumour’s size and grade, nodal status and patient’s age in human breast cancer.

**Materials and methods**

**Patients**

Institutional guidelines including ethical approval and informed consent were followed. Samples from 46 patients with primary invasive breast cancer and 3 patients with benign breast lesions were studied. All patients were surgically treated at (Day General Hospital, Tehran, Iran) during 2004–2005. Breast tissues were collected and preserved by rapid freezing in liquid nitrogen immediately after surgical excision and then were stored at -70°C.

**RT-PCR analysis**

Total RNA was isolated from samples using Tripure Isolation Reagent (Roche, Germany). The mixture of one microgram of total RNA, random hexamer and M-Mulv reverse transcriptase enzyme (Fermentas Co, Canada) was used to create cDNA for each sample, according to the manufacturer’s protocol. In order to avoid he probable DNA contamination for RNA samples, the following stages were performed. We prepared a solution containing the same materials used for cDNA synthesis excluding reverse transcriptase enzyme (negative control 1). This product contains DNA only, with a new concentration similar to the cDNA products. However, in the PCR products of these samples, the presence or absence of any DNA contamination could be observed and detected.

In order to perform DNase treatment, 1 μg of total RNA was digested by DNase (Fermentas Co, Canada) according to the manufacturer’s protocol. Half of DNase treated RNA sample was used to create cDNA. The remaining half of the sample contained all of the materials excluding the reverse transcriptase enzyme (negative control 2), in order to validate the accuracy of DNase treatment process.

The cDNA, DNase treated cDNA and control group samples (to evaluating the accuracy of DNase treatment) were amplified in a 25 μl reaction mixture containing 0.2 mM of each primers and 1U Taq DNA polymerase (Fermentas Co, Canada). For detecting the accuracy of RNA extraction and cDNA synthesis, phosphoglucomutase 1 (PGM1) housekeeping gene was used in RT-PCR performance. The sequence of oligonucleotides which were used for amplification of PGM1, hTR and hTERT genes is listed in table 1. Amplified products were subjected to electrophoresis in 2% agarose gels and were visualized with ethidium bromide.

**Statistical analysis**

The statistical analysis of the data was carried out by using the SPSS software package (SPSS Inc; Chicago, IL, USA;
The Pearson chi-square and Fisher Exact test were performed for the analysis of probable contributions. The significance levels were considered for results with $P$ value lower than 0.05.

**Results**

The mean age of patients with primary breast cancer at diagnosis was 47 years with a range of (28–71). 22.2% (10/45) of the patients were diagnosed at the age of 40 or younger.

$h$TERT and $h$TR genes expression were detected in 38 (82.6%) and 31 (67.4%) breast cancers respectively (Figure 1) (Table 2). $h$TR gene was expressed in all cancers from patients aged $\leq 40$ years (10/10) compared to 60% (21/35) of patients aged $> 40$ years ($p = 0.019$). This significant observation was not seen with $h$TERT. Furthermore, there was a significant association between $h$TERT expression and $h$TR expression when comparing patients aged $\leq 40$ with those who are $> 40$ years old. ($p = 0.018$).

Tumour size range was (0.9–7.0 cm) with a mean of 2.67 cm. We observed no association between tumour size and expression of $h$TR and $h$TERT (Table 3). Moreover, no association was seen between $h$TR, $h$TERT expression and tumour’s grade, stage, axillary node status and pathological type of the tumour.

Finally, two of the benign breast lesion showed $h$TERT expression. However, none of them expressed $h$TR (Table 4).

**Discussion**

It is well established that telomerase activity requires the presence of its subunits; $h$TR and $h$TERT. This study focuses on a new angle in the understanding of telomerase regulation in breast cancer. To our knowledge, this is the first study to examine the association between $h$TR and the prognostic factors in human breast cancer. We used the DNase treatment method for the detection of $h$TR gene expression in order to avoid DNA contamination in RNA extracts. Such contamination may result in false positive findings when RT-PCR technique is used alone in those genes that lack introns or contain pseudogene (such as GAPDH housekeeping gene). Previous studies did not perform the DNase treatment method prior to cDNA synthesis. This resulted in $h$TR being expressed in both cancer and benign cells alike, hence, very little attention was given to $h$TR role in the telomerase regulation and correlation with prognostic factors [30-39].

We found that benign breast lesions showed no expression of $h$TR. Such an observation agrees with other studies; Yashima et al showed that $h$TR expression in stromal cells, including those in fibroadenomas, was negative and increased $h$TR expression was observed in some foci of apocrine metaplasia and atypical hyperplasia [40]. Moreover, a multistage tumorigenesis study in transgenic mice has shown that the RNA component of telomerase is up-regulated in the first stages of tumorigenesis, even in pre-

---

**Table 1: The oligonucleotide sequence of primers used for detecting expression of genes of interest, in the RT-PCR assay.**

| Oligonucleotide | Sequence | Amplified length | Annealing temperature |
|-----------------|----------|------------------|----------------------|
| PGM1–1718       | 5'-TCCGACTGAGGAGGGAGTGC-3' | 386bp | 63°C |
| PGM1–2080       | 5'-TCCGACTGAGGAGGGAGTGC-3' | 316bp | 63°C |
| hTR-F           | 5'-CGGCTGCTTTTGCTCC-3' | 145bp | 67°C |
| hTR-R           | 5'-ACTGCTCGTTCCCTTTCC-3' |        | |
| hTERT–13187     | 5'-CCGAGAGGTCTTCGAGCG-3' |        | |
| hTERT–15411     | 5'-CCGAGAGGTCTTCGAGCG-3' |        | |

---

**Figure 1**
The electropherogram of the PGM1, $h$TR and $h$TERT genes RT-PCR

---

**Table 2: $h$TR and $h$TERT expression in 46 malignant samples**

|          | hTR expression | hTERT expression |
|----------|----------------|------------------|
| Positive | 67.4% (31)     | 82.6% (38)       |
| Negative | 32.6% (15)     | 17.4% (8)        |
cancerous lesions [41]. Therefore, up-regulation of hTR may be a predictive marker for invasive tumor development.

Our observation that hTR expression was associated with younger age (patients aged ≤ 40 years) is a very interesting one. This has implication regarding telomerase gene based therapy or cancer treatment strategies in young patients with breast cancer such as targeting the template region of hTR with anti hTR (such as oligonucleotides) which may inhibit cell telomerase activity and cell proliferation and can lead to a profound induction of programmed cell death [41,42]

We conclude that hTR expression probably plays a greater role in mammary tumourogenesis in younger women (≤ 40 Years.). Tumours in older patients may develop telomerase independent mechanisms for survival.

### References

1. Mokbel K. The Role of Telomerase in Breast Cancer. *European Journal of Surgical Oncology* 2000, 26(5):509-14.
2. Harley CB: Telomere loss: Mitotic clock or genetic time bomb? *Mutation Res* 1991, 256:271-82.
3. Zhu J, Wang H, Bishop J, Blackburn E: Telomerase Extends the Lifespan of Virus-Transformed Human Cells Without Net Telomere Lengthening. *Proceedings of the National Academy of Sciences of the United States of America* 1999, 96(7):3723-8.
4. Kirkpatrick K, Mokbel K: The Significance of Human Telomerase Reverse Transcriptase in Human Cancer. *European Journal of Surgical Oncology* 2001, 27:754-60.
5. Kim NW, Piatyszek MA, Prowse KR, et al.: Specific association of human telomerase activity with immortal cells and cancer. *Science* 1994, 266:2011-2015.
6. Rhyu MS: Telomeres, Telomeres and immortality. *J Nat Cancer Inst* 1995, 87:884-94.
7. Chadeneau C, Hay K, Hirte HW, et al.: Telomerase activity associated with acquisition of malignancy in human colorectal cancer. *Cancer Res* 1995, 55:2533-6.
8. Blackburn EH: Structure and formation of telomeres. *Nature* 1991, 350:569-73.
9. Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB: Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. *EMBO J* 1992, 11:i921-1929.
10. Shay JW, Bacchetti S: A survey of telomerase activity in human cancer. *Eur J Cancer* 1997, 33:787-791.

### Table 3: Correlation between hTR, hTERT and clinicopathological parameters

| Parameter | Freq | hTR expression | hTERT expression | hTR expression samples |
|-----------|------|----------------|------------------|-----------------------|
|           |      | Neg. | Pos. | P     | Neg. | Pos. | P     | Neg. | Pos. | P     |
| Age range | ≤40  | 10 (22.2) | 0 | 10 | 0.019 | 0 | 10 | 0.168 | 0 | 10 | 0.018 |
|           | >40  | 35 (77.8) | 14 | 21 | 8 | 27 | 11 | 16 | 22 (47.8) | 5 | 17 | 0.2 | 4 | 18 | 0.538 | 4 | 14 | 0.27 |
| Size range | ≤2 cm | 22 (47.8) | 5 | 17 | 0.2 | 4 | 18 | 0.538 | 4 | 14 | 0.27 |
|           | 2-5 cm | 19 (41.3) | 9 | 10 | 0.4 | 4 | 15 | 7 | 8 | 21 (51.2) | 9 | 12 | 0.18 | 4 | 16 | 1 | 4 | 12 | 0.7 |
|           | >5 cm | 5 (10.8) | 1 | 4 | 0.4 | 4 | 15 | 7 | 8 | 21 (51.2) | 9 | 12 | 0.18 | 4 | 16 | 1 | 4 | 12 | 0.7 |
| Pathol.   | IDC  | 43 (95.5) | 15 | 28 | 0.593 | 8 | 35 | 0.798 | 12 | 23 | 0.602 |
|           | ILC  | 1 (2.2) | 0 | 1 | 0.018 | 0 | 1 | 0 | 1 | 1 (2.2) | 0 | 1 | 0.018 | 0 | 1 | 0 | 1 | 0.018 |
|           | Muc. | 1 (2.2) | 0 | 1 | 0.018 | 0 | 1 | 0 | 1 | 1 (2.2) | 0 | 1 | 0.018 | 0 | 1 | 0 | 1 | 0.018 |
| Grade     | I    | 4 (9.8) | 1 | 3 | 0.282 | 1 | 3 | 0.958 | 1 | 2 | 0.765 |
|           | II   | 16 (39) | 3 | 13 | 0.282 | 1 | 3 | 0.958 | 1 | 2 | 0.765 |
|           | III  | 21 (51.2) | 9 | 12 | 0.18 | 4 | 16 | 1 | 4 | 12 | 0.7 |
|           | Low  | 20 (48.8) | 4 | 16 | 0.18 | 4 | 16 | 1 | 4 | 12 | 0.7 |
|           | High | 20 (51.2) | 4 | 16 | 0.18 | 4 | 16 | 1 | 4 | 12 | 0.7 |
| ALN Inv.  | Positive | 26 (57.8) | 6 | 20 | 0.2 | 4 | 22 | 0.7 | 5 | 17 | 0.29 |
|           | Negative | 19 (42.2) | 8 | 11 | 0.087 | 2 | 7 | 0.941 | 3 | 4 | 0.045 |
| Stage     | I    | 9 (30) | 4 | 5 | 0.087 | 2 | 7 | 0.941 | 3 | 4 | 0.045 |
|           | IIA  | 7 (23.3) | 2 | 5 | 0.5 | 2 | 5 | 1 | 4 | 2 (6.7) | 1 | 2 | 0.18 | 1 | 2 | 0.18 |
|           | IIB  | 7 (23.3) | 5 | 2 | 1 | 6 | 5 | 1 | 1 | 2 (6.7) | 1 | 2 | 0.18 | 1 | 2 | 0.18 |
|           | IIIA | 6 (20) | 0 | 6 | 1 | 5 | 0 | 5 | 0 | 5 | 0.018 |
|           | IIIB | 1 (3.3) | 0 | 1 | 0.018 | 0 | 1 | 0 | 1 | 0.018 |

### Table 4: Telomerase subunits expression in 3 non-malignant samples

| Pathology | hTR expression | hTERT expression |
|-----------|-----------------|------------------|
| I         | Fibrocystic change | Negative         |
| 2         | Fibrocystic change | Negative         |
| 3         | Benign           | Negative         |

| Pathology | hTR expression | hTERT expression |
|-----------|-----------------|------------------|
| I         | Fibrocystic change | Positive         |
| 2         | Fibrocystic change | Negative         |
| 3         | Benign           | Positive         |
11. Counter CM, Hirte NW, Bacchetti S, Harley CB: Telomerase activity in human ovarian carcinoma. Proc Natl Sci USA 1994, 91:5904-5907.

12. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu et al: The RNA component of human telomerase. Science 1995, 269:1236-1241.

13. Harrington L, McPhail T, Mar V, et al: A mammalian telomerase-associated protein. Science 1997, 275:973-7.

14. Yang H, Kyo S, Takamura M, et al: Autocrine transformation growth factor β suppresses telomerase activity and transcription of human telomerase reverse transcriptase in human cancer cells. Cell Growth Differ 2001, 12:19-27.

15. Nakamura TM, Morin GB, Chapman KB, et al: Telomerase catalytic subunit homologs from fission yeast and human. Science 1997, 277:955-959.

16. Weinrich SL, Pruzan R, Ma L, et al: Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTERT. Nat Genet 1997, 17:498-502.

17. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA, Weinberg RA: hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1995, 80(4):785-95.

18. Yu GL, Bradley JD, Attardi LD, Blackburn EH: In vitro alteration of telomere sequences and senescence caused by mutated Tetrahymena telomerase RNAs. Nature (Lond.) 1990, 344:126-132.

19. Greider CW: Telomerase biochemistry and regulation. Edited by: Telomeres EH Blackburn and CW Greider. (Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press); 1995:35-68.

20. Cohn M, Blackburn EH: Telomerase in yeast. Science 1995, 269:396-400.

21. McEachern MJ, Blackburn EH: Runaway telomere elongation caused by telomerase RNA gene mutations. Nature 1999, 397:403-409.

22. Singer MS, Gottschling DE: TLC1: template RNA component of Saccharomyces cerevisiae telomerase. Science 1994, 266:404-409.

23. Yu GL, Blackburn EH: Developmentally programmed healing of chromosomes by telomerase in Tetrahymena. Cell 1991, 67:823-832.

24. Soder AI, Hoare SF, Muir S, Going JJ, Parkinson EK, Keith WN: Amplification, increased dosage and in situ expression of telomerase RNA gene in human cancer. Oncogene 1997, 14(9):1013-1021.

25. Kirkpatrick KL, Clark G, Ghilichick M, Newbold RF, Molok K: hTERT mRNA expression correlates with telomerase activity in human breast cancer. Eur J Surg Oncol 2003, 29:321-326.

26. Molok K, Parris CN, Radbourne R, Ghilichick M, Newbold RF: Telomerase activity and prognosis in breast cancer. Eur J Surg Oncol 1999, 25:269-272.

27. Molok K, Parris CN, Ghilichick M, Williams G, Newbold RF: The association between telomerase, histopathological parameters, and Ki-67 expression in breast cancer. Am J Surg 1999, 178(1):69-72.

28. Kirkpatrick KL, Ogunkolade W, Elkak AE, Bustin SA, Jenkins P, Ghilichick M, Newbold RF, Molok K: hTERT Expression in human breast cancer and non-cancerous breast tissue; correlation with tumour stage and c-Myc expression. Breast Cancer Res Treat 2003, 77(3):277-284.

29. Elkak AE, Meligonis G, Salhab M, Mitchell B, Blake JR, Newbold RF, Molok K: hTERT protein expression is independent of clinical pathological parameters and c-Myc protein expression in human breast cancer. J Carcinog 2005, 4:17.

30. Hu S, Chan HL, Chen MC, Pang JH: Telomerase expression in benign and malignant skin neoplasms: comparison of three major subunits. J Formos Med Assoc 2002, 101:593-7.

31. Kuniyasu H, Domen T, Hamamoto T, Yokozaki H, Yasaki W, Tahara H, Tahara F: Expression of human telomerase RNA in an early event of stomach carcinogenesis. Jpn J Cancer 1997, 88:103-107.

32. Kyo S, Kanaya M, Takakura M, Tanaka M, Inoue M: Human telomerase reverse transcriptase as a critical determinant of telomerase activity in normal and malignant endometrial tissues. Int J Cancer 1999, 80:60-63.

33. Liu BC-S, Larose I, Weinstein LJ, Ahn M, Weinstein MH, Richie JP: Expression of telomerase subunits in normal and neoplastic prostate epithelial cells isolated by laser capture microdissection. Am Cancer Soc 2001, 92:1943-1948.

34. Nakamura A, Suda T, Homma T, Takakura T, Igarashi M, Waguri N, Kawai H, Mita Y, Aoyagi Y: Increased hTERT expression during transition from adenoma to carcinoma is not associated with promoter methylation. Dig Dis Sci 2004, 49:1504-1512.

35. Onida N, Ogisaka K, Ishikawa T, Takenaka C, Tahara H, Inaba M, Takashima T, Hirakawa K: Telomerase activation and expression of its catalytic subunits in benign and malignant tumors of the parathyroid. Surg Today 2004, 34:389-393.

36. Rohde V, Sattler HP, Bund T, Bonkhoff H, Fixemer T, Bachmann C, Lensch U, Unteregger G, Stoecckle M, Wullich B: Expression of the human telomerase reverse transcriptase is not related to telomerase activity in normal malignant renal tissue. Clin Cancer Res 2000, 6:4803-4809.

37. Ulanner GA, Hu JF, Yu TH, Oruganti H, Giudice LC, Hoffman AR: Regulation of telomerase by alternate splicing of human telomerase reverse transcriptase (hTERT) in normal and neoplastic ovary, endometrium and myometrium. Int J Cancer 2000, 85:330-335.

38. Wang X, Xiao J, Zhao S, Tian Y, Wang G: Expression of telomerase subunits and its relationship with telomerase activity in nasopharyngeal carcinoma. Zhonghua Bing Li Xue Za Zhi 2001, 81:553-556.

39. Wu A, Ichihashi M, Ueda M: Correlation of the human telomerase subunits with telomerase activity in normal skin and skin tumors. Am Cancer Soc 1999, 86:2038-2044.

40. Yasukawa K, Milchgrub S, Gollahon LS, Maitra A, Saboorian MH, Shay JW, Gazdar AF: Telomerase enzyme activity and RNA expression during the multistage pathogenesis of breast carcinoma. Clin Cancer Res 1998, 4(1):229-34.

41. Blasco MA, Rizen M, Greider CW, Hanahan D: Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis. Nat Genet 1996, 12(2):200-204.

42. Zhou JH, Zhang HM, Chen Q, Han DD, Pei F, Zhang LS, Yang DT: Relationship between telomerase activity and its subunit expression and inhibitory effect of antisense hTR on pancreatic carcinoma. World J Gastroenterol 2003, 9:1808-1814.

43. Yatabe N, Kyo S, Kondo S, Kanaya T, Wang Z, Maida Y, Takakura M, Nakamura M, Tanaka M, Inoue M: 2–5A antisense therapy directed against human telomerase RNA inhibits telomerase activity and induces apoptosis without telomere impairment in cervical cancer cells. Cancer Gene Ther 2002, 9:624-30.